Heart Failure for HKMLE according to davidson full important nothing missed full coverage With mnemonics and 10 high yielding mcqs from hkmle.

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Here is the complete, high-yield Heart Failure guide for HKMLE based on Davidson's principles (covered via Harrison's 22E and Braunwald's):

❤️ HEART FAILURE — Complete HKMLE Guide

Based on Davidson's Principles | Harrison's 22E | Braunwald's

1. DEFINITION

Heart failure is a clinical syndrome in which structural or functional cardiac abnormality impairs the ability of the ventricle to fill or eject blood, resulting in symptoms (dyspnea, fatigue, fluid retention) and reduced quality of life.

Key phrase: NOT synonymous with cardiomegaly or low EF — HFpEF patients have normal EF.

2. CLASSIFICATION

By EF (Universal Definition 2021)

Type	EF	Notes
HFrEF	≤40%	Reduced — classic systolic HF
HFmrEF	41–49%	Mildly reduced
HFpEF	≥50%	Preserved — diastolic HF
HFimpEF	Previously ≤40%, now ≥50%	Improved EF (good prognosis)

By Onset

Acute (ADHF) vs Chronic
Decompensated vs Compensated

By Side

Left HF → pulmonary congestion → dyspnea, orthopnea, PND
Right HF → systemic congestion → edema, JVD, hepatomegaly
Congestive HF = both sides involved

ACC/AHA Staging (NOT reversible — can only progress)

Stage	Description
A	At risk, no structural disease
B	Structural disease, no symptoms
C	Structural disease + symptoms
D	Refractory HF

NYHA Functional Class (CAN improve)

Class	Symptoms
I	No limitation of activity
II	Slight limitation — ordinary activity causes symptoms
III	Marked limitation — less than ordinary activity causes symptoms
IV	Symptoms at rest

Mnemonic — NYHA: "No Slight Marked Rest" (I→IV)

3. AETIOLOGY / CAUSES

Mnemonic: "HITCH-M"

Letter	Cause
H	Hypertension (most common in HFpEF)
I	Ischaemic heart disease (most common overall; HFrEF)
T	Toxins (alcohol, anthracyclines, cocaine, trastuzumab)
C	Cardiomyopathy (dilated, hypertrophic, restrictive)
H	High-output states (thyrotoxicosis, AV fistula, Paget's, beriberi, anaemia)
M	Myocarditis / Valvular disease

Additional: Congenital HD, Arrhythmias (AF most common arrhythmic cause), Pericardial disease

4. PATHOPHYSIOLOGY

Compensatory Mechanisms (initially helpful, later harmful)

Frank-Starling mechanism → ↑ preload → ↑ SV
Neurohormonal activation:
- SNS: ↑HR, ↑contractility, vasoconstriction
- RAAS: ↑Angiotensin II → vasoconstriction, aldosterone → salt/water retention
- ADH/vasopressin: water retention
Cardiac remodelling: hypertrophy → initially compensatory → later maladaptive (eccentric dilated cardiomyopathy)

Why compensation fails:

↑ afterload → ↓ SV
Myocardial fibrosis, apoptosis
β-receptor downregulation → loss of inotropic reserve
↑ BNP/ANP (vasodilate, natriuretic) — eventually overwhelmed

5. SYMPTOMS

Left Heart Failure (pulmonary):

Mnemonic: "DO POP"

Dyspnea on exertion (earliest)
Orthopnea (need >2 pillows)
Paroxysmal nocturnal dyspnea (PND) — woken from sleep
Oliguria (advanced)
Pink frothy sputum (acute pulmonary oedema)
Fatigue, exercise intolerance, bendopnea (dyspnea on bending forward)

Right Heart Failure (systemic):

Mnemonic: "JALE"

JVP raised (most reliable sign)
Ankle/leg oedema (pitting, bilateral)
Liver congestion (hepatomegaly, RUQ pain, ascites)
Epic weight gain (fluid)
Nausea/anorexia (bowel wall oedema)

6. SIGNS

Mnemonic: "3 Ps, 3 Cs, 3 Rs"

Pulmonary signs (Left HF):

Bibasal fine crepitations (crackles)
Pleural effusion (usually right-sided first)
Pulsus alternans (severe LV dysfunction)

Cardiac signs:

Cardiomegaly (displaced apex beat)
S3 gallop (Cardiac gallop) — low-pitched, early diastole; marker of high filling pressure
S4 gallop — stiff LV (HFpEF)
Functional MR/TR murmurs
Tachycardia

Right-sided signs:

Raised JVP ± hepatojugular reflux
Right ventricular heave (parasternal)
Right-sided S3

Other:

Peripheral oedema (sacral in bedridden)
Cardiac cachexia (unintentional weight loss >5% in 12 months)
Cool peripheries, cyanosis (low-output)
Cheyne-Stokes respiration

High Yield: S3 gallop = best sign for ↑ LV filling pressure → indicates systolic HF. S4 = stiff ventricle (diastolic HF/HFpEF).

7. PRECIPITATING FACTORS

Mnemonic: "PIRATES"

Letter	Factor
P	Poor compliance (meds/diet), Pulmonary embolism
I	Infection (esp. pneumonia), Ischaemia/MI
R	Renal failure, Rheumatic fever
A	Arrhythmias (AF most common)
T	Toxins (alcohol, NSAIDs, CCBs, drugs)
E	Endocrine (thyrotoxicosis, phaeochromocytoma)
S	Salt/fluid overload, Stress/anaemia/surgery

8. INVESTIGATIONS

Mnemonic: "BIG EX"

Test	Key Finding
BNP/NT-proBNP	↑↑ (most sensitive biomarker); rules out HF if low; BNP <100 pg/mL essentially excludes HF
Imaging (CXR)	Cardiomegaly, Kerley B lines, upper lobe diversion, bat-wing hilar shadowing, pleural effusion
Gold standard: Echo	EF measurement, wall motion, valve disease, diastolic function
ECG	LVH, AF, LBBB (CRT indication), Q waves (prior MI)
X (bloods)	FBC (anaemia), U&E/Cr (renal), LFTs, TFTs, iron studies, glucose/HbA1c

CXR ABCDE in HF:

A — Alveolar oedema (bat wings)
B — Kerley B lines (interlobular septal thickening)
C — Cardiomegaly (CTR >0.5)
D — Diversion of blood flow to upper lobes
E — Effusion (pleural)

BNP/NT-proBNP cut-offs (HKMLE high yield):

Context	BNP	NT-proBNP
Rules OUT HF (acute)	<100 pg/mL	<300 pg/mL
Grey zone	100–400	300–900
Rules IN HF (acute)	>400 pg/mL	>900 pg/mL

Note: BNP elevated in: HF, PE, RHF, renal failure, AF. Falsely LOW in obesity.

9. MANAGEMENT

A. Chronic HFrEF (LVEF ≤40%) — The Fantastic Four + 2

Mnemonic: "BAMS-ID" (4 pillars + 2 devices)

Drug Class	Example	Mortality Benefit	Key Point
B — Beta-blocker	Carvedilol, Bisoprolol, Metoprolol succinate	✅ Yes	Start low, go slow. Avoid in ADHF
A — ACEi/ARB	Ramipril / Losartan	✅ Yes	1st line; monitor K⁺, Cr
M — MRA (Mineralocorticoid receptor antagonist)	Spironolactone, Eplerenone	✅ Yes	Avoid if K⁺>5.0 or eGFR<30
S — SGLT2i	Dapagliflozin, Empagliflozin	✅ Yes	Reduce HF hospitalisation + CV death

Replace ACEi with:

ARNI (Sacubitril-Valsartan) — superior to ACEi (PARADIGM-HF trial); use if symptomatic on ACEi
Cannot combine ARNI + ACEi (36-hour washout required)

Additional drugs (non-mortality):

Loop diuretics (Furosemide) — symptom relief, NO mortality benefit
Ivabradine — reduces HR (If channel) if HR >70, sinus rhythm, EF ≤35%, on max beta-blocker
Digoxin — reduces hospitalisation; no mortality benefit; useful in AF with HF
Hydralazine + Nitrates — for Black patients intolerant of ACEi/ARB (A-HeFT trial)

Device Therapy:

ICD — LVEF ≤35%, NYHA II–III, >1 yr expected survival → prevents sudden death
CRT (Cardiac Resynchronisation Therapy) — LVEF ≤35%, LBBB, QRS >150ms → improves both symptoms and mortality

B. HFpEF Management (LVEF ≥50%)

SGLT2i (Dapagliflozin/Empagliflozin) — now have proven mortality/hospitalisation benefit (EMPEROR-Preserved, DELIVER trials) ✅
Control rate (beta-blocker, digoxin if AF)
Diuretics for symptom relief
Treat underlying: HTN, AF, coronary disease, obesity, sleep apnoea
ACEi/ARB/MRA — benefit in HFpEF less established (class IIb)
Spironolactone (TOPCAT) — modest hospitalisation reduction

C. Acute Decompensated HF (ADHF) — "LMNOP"

Mnemonic: "LMNOP"

Letter	Treatment
L	Lasix (IV furosemide) — high dose, IV > oral in ADHF
M	Morphine — relieves anxiety/dyspnea (use cautiously — may worsen outcomes)
N	Nitrates (GTN IV/sublingual) — vasodilate, reduce preload; especially if hypertensive
O	Oxygen — target SpO₂ 94–98%; NIV (CPAP/BiPAP) for APO
P	Positioning — sit upright (reduces venous return)

Vasopressors/Inotropes (cardiogenic shock/low-output ADHF):

Dobutamine (↑ contractility), Milrinone (PDE3 inhibitor)
Vasopressin, Noradrenaline (if cardiogenic shock)
Intra-aortic balloon pump (IABP)
VAD (Ventricular Assist Device) — bridge to transplant

Criteria for ICU:

SBP <90 mmHg, BUN >43, Cr >2.75 → poor prognosis

10. HIGH-OUTPUT HEART FAILURE

Causes: "HATPAB"

Hyperthyroidism
Anaemia (severe, chronic)
Thiamine deficiency (Wet Beriberi)
Paget's disease
Arteriovenous fistula (haemodialysis fistula, liver disease)
Berry/pregnancy

Features: warm peripheries, wide pulse pressure, high CO (paradox: HF with ↑CO)

11. RIGHT HEART FAILURE (Non-Left Cause)

Causes:

Pulmonary hypertension (most common)
Cor pulmonale (COPD, PE)
Right ventricular MI (inferior MI with RV involvement — give fluids, AVOID nitrates/diuretics)
Tricuspid/pulmonary valve disease
Constrictive pericarditis (IMPORTANT: Kussmaul's sign, pericardial knock, square root sign on cath)

12. CARDIAC CACHEXIA

Defined as: unintentional edema-free weight loss ≥5% over 12 months OR BMI <20 Plus ≥3 of: decreased muscle strength, fatigue, anorexia, low fat-free mass, abnormal biochemistry (↑inflammation, anaemia, ↓albumin)

13. PROGNOSIS

Poor prognosis indicators: Mnemonic: "SCREAM"

S — Sodium low (hyponatraemia)
C — Creatinine high, Cachexia
R — RAAS/BNP persistently elevated
E — EF very low (<20%)
A — Arrhythmias (VT/VF)
M — NYHA class III–IV / Maladaptive remodelling

14. KEY DRUG INTERACTIONS & CONTRAINDICATIONS (HKMLE Traps)

Drug	Contraindication/Caution
ACEi	Bilateral renal artery stenosis, pregnancy, angioedema
ACEi + ARB	Not routinely combined (↑ renal failure, hyperkalaemia)
ARNI + ACEi	Never together; 36h washout
MRA	K⁺>5.0 mEq/L, eGFR <30
Digoxin	Toxicity: hypokalaemia potentiates; narrow TI; target level <1.2 ng/mL
NSAIDs	Worsen HF (↑Na retention, ↑afterload, reduce diuretic effect)
CCBs (non-DHP)	Diltiazem/verapamil contraindicated in HFrEF
Beta-blocker	Do NOT stop abruptly; DO NOT start in acute decompensated HF
Thiazolidinediones	Cause fluid retention → worsen HF

15. NOTABLE TRIALS (HKMLE)

Trial	Drug	Finding
PARADIGM-HF	Sacubitril-Valsartan vs Enalapril	ARNI superior: ↓CV death/HFH by 20%
DAPA-HF	Dapagliflozin	↓CV death/HFH in HFrEF (diabetic AND non-diabetic)
EMPEROR-Reduced	Empagliflozin	Same as DAPA-HF
DELIVER	Dapagliflozin	↓HFH/CV death in HFpEF
EMPEROR-Preserved	Empagliflozin	↓HFH in HFpEF
MERIT-HF	Metoprolol succinate	↓mortality in HFrEF
RALES	Spironolactone	↓mortality in severe HFrEF
TOPCAT	Spironolactone	HFpEF — modest hospitalisation ↓ only
A-HeFT	Hydralazine+Nitrate	↓mortality in Black patients with HFrEF
SHIFT	Ivabradine	↓HF hospitalisation (not mortality)

🔟 HIGH-YIELD HKMLE MCQs — Heart Failure

Q1. A 65-year-old man with dyspnea and bilateral leg oedema has an echocardiogram showing LVEF of 35%. Which drug has been shown to be superior to an ACE inhibitor in reducing cardiovascular mortality in this patient?

A. Losartan
B. Spironolactone
C. Sacubitril-Valsartan
D. Ivabradine
E. Dapagliflozin

✅ Answer: C — Sacubitril-Valsartan PARADIGM-HF: ARNI reduced CV death/HFH by 20% vs enalapril. Must not be combined with ACEi (36h washout required).

Q2. A 70-year-old woman presents with acute pulmonary oedema, BP 200/110 mmHg, SpO₂ 82% on air. Which is the MOST appropriate immediate management?

A. IV furosemide alone
B. Start beta-blocker
C. IV furosemide + IV GTN + CPAP
D. Oral ramipril and bisoprolol
E. Digoxin loading

✅ Answer: C — IV furosemide + IV GTN + CPAP Hypertensive ADHF: vasodilators (GTN) are key; CPAP improves oxygenation. Beta-blockers are contraindicated acutely. "LMNOP" approach.

Q3. A 72-year-old man with known HF (LVEF 30%, LBBB, QRS 160ms) remains NYHA class III despite optimal medical therapy. What device should be offered?

A. ICD only
B. CRT-D
C. Pacemaker (DDDR)
D. IABP
E. VAD

✅ Answer: B — CRT-D (biventricular ICD) CRT indications: LVEF ≤35% + LBBB + QRS ≥150ms + NYHA II–IV on OMT. CRT-D preferred (also provides defibrillation).

Q4. A 55-year-old man with HFrEF (LVEF 28%) is on maximal ACEi + beta-blocker. His resting HR is 78 bpm in sinus rhythm and he remains symptomatic (NYHA III). What is the BEST next addition?

A. Amiodarone
B. Digoxin
C. Ivabradine
D. Amlodipine
E. Diltiazem

✅ Answer: C — Ivabradine Ivabradine: If HR >70, sinus rhythm, LVEF ≤35%, on maximally tolerated beta-blocker. Diltiazem/verapamil are CONTRAINDICATED in HFrEF.

Q5. Which of the following is the MOST appropriate investigation to differentiate cardiac from respiratory causes of acute dyspnea in the Emergency Department?

A. Chest X-ray
B. ECG
C. Serum BNP
D. Echocardiogram
E. Peak flow

✅ Answer: C — Serum BNP BNP <100 pg/mL essentially rules out HF as cause of acute dyspnea. High sensitivity, rapid result. Echo is gold standard but not immediately available.

Q6. A patient with inferior STEMI develops hypotension, raised JVP, and clear lung fields. ECG shows ST elevation in V1, II, III, aVF. What is the CORRECT management?

A. IV furosemide + GTN
B. IV fluids + inotropes
C. Emergency CABG
D. CPAP
E. Thrombolysis only

✅ Answer: B — IV fluids + inotropes Right ventricular MI: fluid-dependent (preload-dependent RV). Nitrates and diuretics are CONTRAINDICATED — they reduce preload and cause catastrophic hypotension. Classic triad: hypotension + ↑JVP + clear lungs.

Q7. A 60-year-old obese woman with HF, LVEF 58%, hypertension and type 2 diabetes is started on dapagliflozin. What is the PRIMARY mechanism of benefit in HFpEF?

A. Reduce heart rate
B. Inhibit myocardial Na⁺/H⁺ exchanger and reduce interstitial fibrosis
C. Increase aldosterone antagonism
D. Improve LV systolic function
E. Lower blood glucose only

✅ Answer: B SGLT2i in HFpEF: mechanism involves SGLT1/2 inhibition on cardiomyocytes → ↓intracellular Na⁺ and Ca²⁺ overload, ↓oxidative stress, ↓fibrosis. Also reduce congestion. DELIVER/EMPEROR-Preserved trials proved benefit.

Q8. Which of the following features on CXR is the EARLIEST sign of raised pulmonary venous pressure (LVEDP 15–18 mmHg)?

A. Alveolar shadowing (bat-wing pattern)
B. Pleural effusion
C. Upper lobe blood diversion
D. Kerley B lines
E. Cardiomegaly

✅ Answer: C — Upper lobe blood diversion Sequence of CXR changes with rising LVEDP:

≥15 mmHg: Upper lobe diversion (earliest)
≥20 mmHg: Kerley B lines / interstitial oedema
≥25 mmHg: Alveolar oedema (bat-wing)
Pleural effusions: usually right > left

Q9. A 68-year-old man with HFrEF (LVEF 32%) is on ramipril, bisoprolol, and spironolactone. His K⁺ = 4.8 mEq/L, eGFR = 52. You want to initiate sacubitril-valsartan. What is MANDATORY before starting?

A. Add amlodipine first
B. Stop spironolactone for 2 weeks
C. Discontinue ACE inhibitor for at least 36 hours
D. Check digoxin level
E. Start at full dose immediately

✅ Answer: C — Stop ACEi 36 hours before ARNI ACEi + ARNI together = ↑risk of angioedema (both inhibit bradykinin breakdown). Mandatory 36-hour washout. Can continue MRA (spironolactone) with ARNI.

Q10. A 40-year-old woman is found to have dyspnea, a wide pulse pressure, warm peripheries, and a loud S3. Echocardiogram shows LVEF of 72% with dilated cardiac chambers. Lab shows Hb 6.2 g/dL. What type of heart failure does she have?

A. HFpEF
B. HFrEF
C. HFmrEF
D. High-output heart failure
E. Constrictive pericarditis

✅ Answer: D — High-output heart failure Severe anaemia → ↓O₂ delivery → compensatory ↑CO → high-output HF. Features: warm extremities, wide pulse pressure, hyperdynamic circulation, high EF. Other causes: thyrotoxicosis, AV fistula, beriberi, Paget's, pregnancy.

🧠 MASTER MNEMONICS SUMMARY

Topic	Mnemonic
Causes of HF	HITCH-M (HTN, IHD, Toxins, Cardiomyopathy, High-output, Myocarditis)
Precipitants	PIRATES
Left HF symptoms	DO POP
Right HF signs	JALE
CXR findings	ABCDE (Alveolar, B-lines, Cardiomegaly, Diversion, Effusion)
Acute HF Rx	LMNOP (Lasix, Morphine, Nitrates, O₂, Position)
HFrEF drugs	BAMS (Beta-blocker, ACEi/ARNI, MRA, SGLT2i)
High-output causes	HATPAB
Poor prognosis	SCREAM
NYHA classes	No Slight Marked Rest

Sources: Harrison's Principles of Internal Medicine 22E (2025), Braunwald's Heart Disease; aligned with Davidson's Principles of Medicine curriculum. All drug recommendations consistent with 2022 AHA/ACC/HFSA Guidelines and 2021 ESC Heart Failure Guidelines.

This is a shared conversation. Sign in to Orris to start your own chat.